Regenxbio Inc (RGNX)
9.72
+0.37
(+3.96%)
USD |
NASDAQ |
Oct 04, 16:00
9.74
+0.02
(+0.21%)
After-Hours: 20:00
Regenxbio Shareholders Equity (Annual): 311.74M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 311.74M |
December 31, 2022 | 516.20M |
December 31, 2021 | 764.30M |
December 31, 2020 | 377.75M |
December 31, 2019 | 450.20M |
December 31, 2018 | 508.85M |
Date | Value |
---|---|
December 31, 2017 | 183.03M |
December 31, 2016 | 161.74M |
December 31, 2015 | 216.81M |
December 31, 2014 | -5.698M |
December 31, 2013 | -2.143M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
311.74M
Minimum
2023
764.30M
Maximum
2021
484.04M
Average
450.20M
Median
2019
Shareholders Equity (Annual) Benchmarks
Sarepta Therapeutics Inc | 859.34M |
Catalyst Pharmaceuticals Inc | 387.88M |
Vertex Pharmaceuticals Inc | 17.58B |
Edgewise Therapeutics Inc | 318.83M |
Entrada Therapeutics Inc | 242.36M |